New insights into the crossroads between EMT and stemness in the context of cancer

Journal of Clinical Medicine

Volumn 5, Issue 3, 2016, Pages

  Fabregat, Isabel ^a,b   Malfettone, Andrea ^a   Soukupova, Jitka ^a  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

CD133; CD44; EMT; MET; Prrx; Snail; Stem; Transforming Growth Factor (TGF ); Twist; Zeb

Indexed keywords

ABC TRANSPORTER; CD133 ANTIGEN; FIBROBLAST GROWTH FACTOR; HERMES ANTIGEN; INTERLEUKIN 6; LONG UNTRANSLATED RNA; MACROPHAGE MIGRATION INHIBITION FACTOR; MOCETINOSTAT; NOTCH RECEPTOR; PROTEIN BCL XL; PROTEIN MCL 1; SCATTER FACTOR; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SOX9; TRANSCRIPTION FACTOR TWIST; TRANSCRIPTION FACTOR ZEB1; TRANSFORMING GROWTH FACTOR BETA; UVOMORULIN; WNT PROTEIN;

BREAST CARCINOMA; CANCER STEM CELL; CELL PROLIFERATION; DNA DAMAGE; EMBRYONIC STEM CELL; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; HUMAN; NEOPLASM; REVIEW; STEMNESS; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

EID: 84973456757     PISSN: None     EISSN: 20770383     Source Type: Journal    
DOI: 10.3390/jcm5030037     Document Type: Review

References (89)

1. Nieto, M.A. Epithelial plasticity: A common theme in embryonic and cancer cells. Science 2013, 342. [CrossRef] [PubMed]
2. Thiery, J.P., Acloque, H., Huang, R.Y.J., Nieto, A. M. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139, 871-890. [CrossRef] [PubMed]
3. Thiery, J.P. Epithelial-mesenchymal transitin in tumour progression. Nat. Rev. Cancer 2002, 2, 445-454. [CrossRef] [PubMed]
4. Medema, J.P. Cancer stem cells: The challenges ahead. Nat. Cell Biol. 2013, 15, 338-344. [CrossRef] [PubMed]
5. Mani, S.A., Guo, W., Liao, M.-J., Eaton, E.N., Ayyanan, A., Zhou, A.Y., Brooks, M., Reinhard, F., Zhang, C.C., Shipitsin, M., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133, 704-715. [CrossRef] [PubMed]
6. Wellner, U., Schubert, J., Burk, U.C., Schmalhofer, O., Zhu, F., Sonntag, A., Waldvogel, B., Vannier, C., Darling, D., Hausen, A.Z., et al. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting micrornas. Nat. Cell Biol. 2009, 11, 1487-1495. [CrossRef] [PubMed]
7. Ocaña, O.H., Córcoles, R., Fabra, A., Moreno-Bueno, G., Acloque, H., Vega, S., Barrallo-Gimeno, A., Cano, A., Nieto, M.A. Metastatic colonization requires the repression of the epithelial-mesenchymal transition inducer PRRX1. Cancer Cell 2012, 22, 709-724. [CrossRef] [PubMed]
8. Tsai, J.H., Donaher, J.L., Murphy, D.A., Chau, S., Yang, J. Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 2012, 22, 725-736. [CrossRef] [PubMed]
9. Gonzalez, D.M., Medici, D. Signaling mechanisms of the epithelial-mesenchymal transition. Sci. Signal. 2014, 23. [CrossRef] [PubMed]
10. Fabregat, I., Fernando, J., Mainez, J., Sancho, P. TGF- β signaling in cancer treatment. Curr. Pharm. Des. 2014, 20, 2934-2947. [CrossRef] [PubMed]
11. Caja, L., Sancho, P., Bertran, E., Fabregat, I. Dissecting the effect of targeting the epidermal growth factor receptor on TGF- β-induced-apoptosis in human hepatocellular carcinoma cells. J. Hepatol. 2011, 55, 351-358. [CrossRef] [PubMed]
12. Drabsch, Y., Dijke, P.T. TGF- β signalling and its role in cancer progression and metastasis. Cancer Metastasis Rev. 2012, 3-4, 553-568. [CrossRef] [PubMed]
13. Nieto, M.A., Cano, A. The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin. Cancer Biol. 2012, 22, 361-368. [CrossRef] [PubMed]
14. Han, Y., Ye, J., Wu, D., Wu, P., Chen, Z., Chen, J., Gao, S., Huang, J. LEIGC long non-coding RNA acts as a tumor suppressor in gastric carcinoma by inhibiting the epithelial-to-mesenchymal transition. BMC Cancer 2014, 14, 932. [CrossRef] [PubMed]
15. Díaz, V., Viñas-Castells, R., Herreros, A.G.D. Regulation of the protein stability of EMT transcription factors. Cell Adhes. Migr. 2014, 8, 418-428. [CrossRef] [PubMed]
16. Bill, R., Christofori, G. The relevance of EMT in breast cancer metastasis: Correlation or causality? FEBS Lett. 2015, 589, 1577-1587. [CrossRef] [PubMed]
17. Cano, A., Pérez-Moreno, M.A., Rodrigo, I., Locascio, A., Blanco, M.J., Barrio, M.G.D., Portillo, F., Nieto, M.A. The transcription factor Snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat. Cell Biol. 2000, 2, 76-83. [CrossRef] [PubMed]
18. Batlle, E., Sancho, E., Francí, C., Domínguez, D., Monfar, M., Baulida, J., Herreros, A.G.D. The transcription factor Snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat. Cell Biol. 2000, 2, 84-89. [CrossRef] [PubMed]
19. Blanco, M.J., Moreno-Bueno, G., Sarrio, D., Locascio, A., Cano, A., Palacios, J., Nieto, M.A. Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene 2002, 21, 3241-3246. [CrossRef] [PubMed]
20. Olmeda, D., Moreno-Bueno, G., Flores, J.M., Fabra, A., Portillo, F., Cano, A. Snai1 is required for tumor growth and lymph node metastasis of human breast carcinoma MDA-MB-231 cells. Cancer Res. 2007, 67, 11721-11731. [CrossRef] [PubMed]
21. Yang, J., Mani, S.A., Donaher, J.L., Ramaswamy, S., Itzykson, R.A., Come, C., Savagner, P., Gitelman, I., Richardson, A., Weinberg, R.A. Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell 2004, 117, 927-939. [CrossRef] [PubMed]
22. Peinado, H., Olmeda, D., Cano, A. Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat. Rev. Cancer 2007, 7, 415-428. [CrossRef] [PubMed]
23. Puisieux, A., Brabletz, T., Caramel, J. Oncogenic roles of EMT-inducing transcription factors. Nat. Cell Biol. 2014, 16, 488-494. [CrossRef] [PubMed]
24. Lindsey, S., Langhans, S.A. Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front. Oncol. 2014, 4, 358. [CrossRef] [PubMed]
25. Trimboli, A.J., Fukino, K., Bruin, A.D., Wei, G., Shen, L., Tanner, S.M., Creasap, N., Rosol, T.J., Robinson, M.L., Eng, C., et al. Direct evidence for epithelial-mesenchymal transitions in breast cancer. Cancer Res. 2008, 68, 937-945. [CrossRef] [PubMed]
26. McGirt, L.Y., Jia, P., Baerenwald, D.A., Duszynski, R.J., Dahlman, K.B., Zic, J.A., Zwerner, J.P., Hucks, D., Dave, U., Zhao, Z., et al. Whole-genome sequencing reveals oncogenic mutations in mycosis fungoides. Blood 2015, 126, 508-519. [CrossRef] [PubMed]
27. Barrallo-Gimeno, A., Nieto, A.M. The Snail genes as inducers of cell movement and survival: Implications in development and cancer. Development 2005, 132, 3151-3161. [CrossRef] [PubMed]
28. Inoue, A., Seidel, M., Wu, W., Kamizono, S., Ferrando, A., Bronson, R., Iwasaki, H., Akashi, K., Morimoto, A., Hitzler, J., et al. Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. Cancer Cell 2002, 2, 279-288. [CrossRef]
29. Vega, S., Morales, A.V., Ocaña, O.H., Valdés, F., Fabregat, I., Nieto, M.A. Snail blocks the cell cycle and confers resistance to cell death. Genes Dev. 2004, 18, 1131-1143. [CrossRef] [PubMed]
30. Franco, D.L., Mainez, J., Vega, S., Sancho, P., Murillo, M.M., Frutos, C.A.D., Castillo, G.D., López-Blau, C., Fabregat, I., Nieto, M.A. Snail1 suppresses TGF-β-induced apoptosis and is sufficient to trigger EMT in hepatocytes. J. Cell Sci. 2010, 123, 3467-3477. [CrossRef] [PubMed]
31. Beck, B., Lapouge, G., Rorive, S., Drogat, B., Desaedelaere, K., Delafaille, S., Dubois, C., Salmon, I., Willekens, K., Marine, J., et al. Different levels of Twist1 regulate skin tumor initiation, stemness, and progression. Cell Stem Cell 2015, 16, 67-79. [CrossRef] [PubMed]
32. Sánchez, A., Álvarez, A.M., Pedrosa, J.M.L., Roncero, C., Benito, M., Fabregat, I. Apoptotic response to TGF- β in fetal hepatocytes depends upon their state of differentiation. Exp. Cell Res. 1999, 252, 281-291. [CrossRef] [PubMed]
33. Valdés, F., Álvarez, A.M., Locascio, A., Vega, S., Herrera, B., Fernández, M., Benito, M., Nieto, M.A., Fabregat, I. The epithelial mesenchymal transition confers resistance to the apoptotic effects of transforming growth factor β in fetal rat hepatocytes. Mol. Cancer Res. 2002, 1, 68-78. [PubMed]
34. Caja, L., Bertran, E., Campbell, J., Fausto, N., Fabregat, I. The transforming growth factor- β (TGF- β) mediates acquisition of a mesenchymal stem cell-like phenotype in human liver cells. J. Cell. Physiol. 2010, 226, 1214-1223. [CrossRef] [PubMed]
35. Castillo, G.D., Alvarez-Barrientos, A., Carmona-Cuenca, I., Fernández, M., Sánchez, A., Fabregat, I. Isolation and characterization of a putative liver progenitor population after treatment of fetal rat hepatocytes with TGF- β. J. Cell. Physiol. 2008, 215, 846-855. [CrossRef] [PubMed]
36. Morel, A., Lièvre, M., Thomas, C., Hinkal, G., Ansieau, S., Puisieux, A. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS ONE 2008, 3, e2888. [CrossRef] [PubMed]
37. Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell 2012, 148, 349-361. [CrossRef] [PubMed]
38. Dang, H., Ding, W., Emerson, D., Rountree, C.B. Snail1 induces epithelial-to-mesenchymal transition and tumor initiating stem cell characteristics. BMC Cancer 2011, 11, 396. [CrossRef] [PubMed]
39. Wu, K., Ding, J., Chen, C., Sun, W., Ning, B.-F., Wen, W., Huang, L., Han, T., Yang, W., Wang, C., et al. Hepatic transforming growth factor β gives rise to tumor-initiating cells and promotes liver cancer development. Hepatology 2012, 56, 2255-2267. [CrossRef] [PubMed]
40. Fernando, J., Malfettone, A., Cepeda, E.B., Vilarrasa-Blasi, R., Bertran, E., Raimondi, G., Fabra, A., Alvarez-Barrientos, A., Fernández-Salguero, P., Fernández-Rodríguez, C.M., et al. A mesenchymal-like phenotype and expression of CD44 predict lack of apoptotic response to sorafenib in liver tumor cells. Int. J. Cancer 2015, 136, E161-E172. [CrossRef] [PubMed]
41. Bertran, E., Crosas-Molist, E., Sancho, P., Caja, L., Lopez-Luque, J., Navarro, E., Egea, G., Lastra, R., Serrano, T., Ramos, E., et al. Overactivation of the TGF- β pathway confers a mesenchymal-like phenotype and CXCR4 dependent migratory properties to liver tumor cells. Hepatology 2013, 58, 2032-2044. [CrossRef] [PubMed]
42. Kurrey, N., Jalgaonkar, S., Joglekar, A., Ghanate, A., Chaskar, P., Doiphode, R., Bapat, S. Snail and Slug mediate radioresistance and chemoresistance by antagonizing p53-mediated apoptosis and acquiring a stem-like phenotype in ovarian cancer cells. Stem Cells 2009, 27, 2059-2068. [CrossRef] [PubMed]
43. Yang, M.H., Hsu, D.S.S., Wang, H.W., Wang, H.J., Lan, H.Y., Yang, W.H., Huang, C.H., Kao, S.Y., Tzeng, C.H., Tai, S.K., et al. Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition. Nat. Cell Biol. 2010, 12, 982-992. [CrossRef] [PubMed]
44. Chang, C.J., Chao, C.H., Xia, W., Yang, J.Y., Xiong, Y., Li, C.W., Yu, W.H., Rehman, S.K., Hsu, J.L., Lee, H.H., et al. p53 regulates epithelial-mesenchymal transition and stem cell properties through modulating miRNAs. Nat. Cell Biol. 2011, 13, 317-323. [CrossRef] [PubMed]
45. Tschaharganeh, D.F., Xue, W., Calvisi, D.F., Evert, M., Michurina, T.V., Dow, L.E., Banito, A., Katz, S.F., Kastenhuber, E.R., Weissmueller, S., et al. p53-dependent Nestin regulation links tumor suppression to cellular plasticity in liver cancer. Cell 2014, 158, 579-592. [CrossRef] [PubMed]
46. Sánchez-Tilló, E., Barrios, O.D., Siles, L., Cuatrecasas, M., Castells, A., Postigo, A. B-catenin/TCF4 complex induces the epithelial-to-mesenchymal transition (EMT)-activator ZEB1 to regulate tumor invasiveness. Proc. Natl. Acad. Sci. USA 2011, 108, 19204-19209. [CrossRef] [PubMed]
47. Mima, K., Okabe, H., Ishimoto, T., Hayashi, H., Nakagawa, S., Kuroki, H., Watanabe, M., Beppu, T., Tamada, M., Nagano, O., et al. CD44s regulates the TGF- β -mediated mesenchymal phenotype and is associated with poor prognosis in patients with hepatocellular carcinoma. Cancer Res. 2012, 23, 3414-3423. [CrossRef] [PubMed]
48. Nomura, A., Banerjee, S., Chugh, R., Dudeja, V., Yamamoto, M., Vickers, S.M., Saluja, A.K. CD133 initiates tumors, induces epithelial-mesenchymal transition and increases metastasis in pancreatic cancer. Oncotarget 2015, 6, 8313-8322. [CrossRef] [PubMed]
49. Preca, B.-T., Bajdak, K., Mock, K., Sundararajan, V., Pfannstiel, J., Maurer, J., Wellner, U., Hopt, U.T., Brummer, T., Brabletz, S., et al. A self-enforcing CD44s/ZEB1 feedback loop maintains EMT and stemness properties in cancer cells. Int. J. Cancer 2015, 137, 2566-2577. [CrossRef] [PubMed]
50. Li, R., Liang, J., Ni, S., Zhou, T., Qing, X., Li, H., He, W., Chen, J., Li, F., Zhuang, Q., et al. A mesenchymal-to-epithelial transition initiates and is required for the nuclear reprogramming of mouse fibroblasts. Cell Stem Cell 2010, 7, 51-63. [CrossRef] [PubMed]
51. Celià-Terrassa, T., Meca-Cortés, Ó., Mateo, F., Paz, A.M.D., Rubio, N., Arnal-Estapé, A., Ell, B.J., Bermudo, R., Díaz, A., Guerra-Rebollo, M., et al. Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J. Clin. Investig. 2012, 122, 1849-1868. [CrossRef] [PubMed]
52. Tran, H., Luitel, K., Kim, M., Zhang, K., Longmore, G., Tran, D. Transient Snail1 expression is necessary for metastatic competence in breast cancer. Cancer Res. 2014, 74, 6330-6340. [CrossRef] [PubMed]
53. Guo, W., Keckesova, Z., Donaher, J.L., Shibue, T., Tischler, V., Reinhardt, F., Itzkovitz, S., Noske, A., Zürrer-Härdi, U., Bell, G., et al. Slug and Sox9 cooperatively determine the mammary stem cell state. Cell 2012, 148, 1015-1028. [CrossRef] [PubMed]
54. Luanpitpong, S., Li, J., Manke, A., Brundage, K., Ellis, E., McLaughlin, S., Angsutararux, P., Chanthra, N., Voronkova, M., Chen, Y., et al. SLUG is required for SOX9 stabilization and functions to promote cancer stem cells and metastasis in human lung carcinoma. Oncogene 2015. [CrossRef] [PubMed]
55. Schmidt, J.M., Panzilius, E., Bartsch, H.S., Irmler, M., Beckers, J., Kari, V., Linnemann, J.R., Dragoi, D., Hirschi, B., Kloos, U.J., et al. Stem-cell-like properties and epithelial plasticity arise as stable traits after transient Twist1 activation. Cell Rep. 2015, 10, 131-139. [CrossRef] [PubMed]
56. Stankic, M., Pavlovic, S., Chin, Y., Brogi, E., Padua, D., Norton, L., Massagué, J., Benezra, R. TGF-β-Id1 signaling opposes Twist1 and promotes metastatic colonization via a mesenchymal-to-epithelial transition. Cell Rep. 2013, 5, 1228-1242. [CrossRef] [PubMed]
57. Costa-Silva, B., Aiello, N., Ocean, A., Singh, S., Zhang, H., Thakur, B., Becker, A., Hoshino, A., Mark, M., Molina, H., et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat. Cell Biol. 2015, 17, 816-826. [CrossRef] [PubMed]
58. Hoshino, A., Costa-Silva, B., Shen, T., Rodrigues, G., Hashimoto, A., Tesic, M.M., Molina, H., Kohsaka, S., Giannatale, A.D., Ceder, S., et al. Tumour exosome integrins determine organotropic metastasis. Nature 2015, 527, 329-335. [CrossRef] [PubMed]
59. Grande, M.T., Sánchez-Laorden, B., López-Blau, C., Frutos, C.A.D., Boutet, A., Arévalo, M., Rowe, R.G., Weiss, S.J., López-Novoa, J.M., Nieto, M.A. Snail1-induced partial epithelial-to-mesenchymal transition drives renal fibrosis in mice and can be targeted to reverse established disease. Nat. Med. 2015, 21, 989-997. [CrossRef] [PubMed]
60. Lovisa, S., LeBleu, V.S., Tampe, B., Sugimoto, H., Vadnagara, K., Carstens, J.L., Wu, C.-C., Hagos, Y., Burckhardt, B.C., Pentcheva-Hoang, T., et al. Epithelial-to-mesenchymal transition induces cell cycle arrest and parenchymal damage in renal fibrosis. Nat. Med. 2015, 21, 998-908. [CrossRef] [PubMed]
61. Brabletz, T. EMT and MET in metastasis: Where are the cancer stem cells? Cancer Cell 2012, 22, 699-701. [CrossRef] [PubMed]
62. Ombrato, L., Malanchi, I. The EMT universe: Space between cancer cell dissemination and metastasis initiation. Crit. Rev. Oncog. 2014, 19, 349-361. [CrossRef] [PubMed]
63. Ye, X., Weinberg, R.A. Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 2015, 25, 675-686. [CrossRef] [PubMed]
64. Jolly, M.K., Jia, D., Boareto, M., Mani, S.A., Pienta, K.J., Ben-Jacob, E., Levine, H. Coupling the modules of EMT and stemness: A tunable “stemness window” model. Oncotarget 2015, 6, 25161-25174. [CrossRef] [PubMed]
65. Li, Y., Ma, J., Qian, X., Wu, Q., Xia, J., Miele, L., Sarkar, F., Wang, Z. Regulation of EMT by Notch signaling pathway in tumor progression. Curr. Cancer Drug Targets 2013, 13, 957-962. [CrossRef] [PubMed]
66. Wang, Z., Li, Y., Kong, D., Banerjee, S., Ahmad, A., Azmi, A., Ali, S., Abbruzzese, J., Gallick, G., Sarkar, F. Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res. 2009, 69, 2400-2407. [CrossRef] [PubMed]
67. Wang, X., Ling, M., Guan, X., Tsao, S., Cheung, H., Lee, D., Wong, Y. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene 2004, 23, 474-482. [CrossRef] [PubMed]
68. Saxena, M., Stephens, M., Pathak, H., Rangarajan, A. Transcription factors that mediate epithelial-mesenchymal transition lead to multidrug resistance by upregulating ABC transporters. Cell Death Dis. 2011, 2, e179. [CrossRef] [PubMed]
69. Kong, Y., Peng, Y., Liu, Y., Xin, H., Zhan, X., Tan, W. Twist1 and Snail link Hedgehog signaling to tumor-initiating cell-like properties and acquired chemoresistance independently of ABC transporters. Stem Cells 2015, 33, 1063-1074. [CrossRef] [PubMed]
70. Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T.C., Choi, H., Rayes, T.E., Ryu, S., Troeger, J., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 2015, 527, 472-476. [CrossRef] [PubMed]
71. Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.-C., LeBleu, V.S., Kalluri, R. Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 2015, 527, 525-530. [CrossRef] [PubMed]
72. Mitra, A., Mishra, L., Li, S. EMT, CTCs, CSCs in tumor relapse and drug-resistance. Oncotarget 2015, 6, 10697-10711. [CrossRef] [PubMed]
73. Zhang, N., Li, R., Tao, K., Cao, D., Ti, Z., Ding, R., Cai, L., Zhang, F., Dou, K. Characterization of a stem-like population in hepatocellular carcinoma MHCC97 cells. Oncol. Rep. 2010, 23, 827-831. [PubMed]
74. Liu, T., Xu, F., Du, X., Lai, D., Liu, T., Zhao, Y., Huang, Q., Jiang, L., Huang, W., Cheng, W., et al. Establishment and characterization of multi-drug resistant, prostate carcinoma-initiating stem like cells from human prostate cancer cell lines 22RV1. Mol. Cell. Biochem. 2010, 340, 265-273. [CrossRef] [PubMed]
75. Lim, S., Becker, A., Zimmer, A., Lu, J., Buettner, R., Kirfel, J. SNAI1-mediated epithelial-mesenchymal transition confers chemoresistance and cellular plasticity by regulating genes involved in cell death and stem cell maintenance. PLOS ONE 2015, 8, e66558. [CrossRef] [PubMed]
76. Ong, C., Kim, L., Kong, H., Low, L., Iacopetta, B., Soong, R., Salto-Tellez, M. CD133 expression predicts for non-response to chemotherapy in colorectal cancer. Mod. Pathol. 2010, 23, 450-457. [CrossRef] [PubMed]
77. Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., Abdulkadir, I., Lu, L., Irvin, D., Black, K., Yu, J. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 2006, 5, 67. [CrossRef] [PubMed]
78. Sarvi, S., Mackinnon, A., Avlonitis, N., Bradley, M., Rintoul, R., Rassl, D., Wang, W., Forbes, S., Gregory, C., Sethi, T. CD133+ cancer stem-like cells in small cell lung cancer are highly tumorigenic and chemoresistant but sensitive to a novel neuropeptide antagonist. Cancer Res. 2014, 74, 1554-1565. [CrossRef] [PubMed]
79. Bates, R.C., Edwards, N.S., Burns, G.F., Fisher, D.E. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. Cancer Res. 2001, 61, 5275-5283. [PubMed]
80. Bourguignon, L., Peyrollier, K., Xia, W., Gilad, E. Hyaluronan-CD44 interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 gene expression, and ankyrin-regulated multidrug efflux in breast and ovarian tumor cells. J. Biol. Chem. 2008, 283, 17635-17651. [CrossRef] [PubMed]
81. Bourguignon, L., Shiina, M., Li, J. Hyaluronan-CD44 interaction promotes oncogenic signaling, microrna functions, chemoresistance, and radiation resistance in cancer stem cells leading to tumor progression. Adv. Cancer Res. 2014, 123, 255-275. [PubMed]
82. Hashimoto, N., Tsunedomi, R., Yoshimura, K., Watanabe, Y., Hazama, S., Oka, M. Cancer stem-like sphere cells induced from de-differentiated hepatocellular carcinoma-derived cell lines possess the resistance to anti-cancer drugs. BMC Cancer 2014, 14, 722. [CrossRef] [PubMed]
83. Wang, Z., Li, Y., Ahmad, A., Azmi, A.S., Kong, D., Banerjee, S. Targeting miRNAs involved in cancer stem cell and EMT regulation: An emerging concept in overcoming drug resistance. Drug Resist. Updat. 2010, 13, 109-118. [CrossRef] [PubMed]
84. Garg, M. Targeting microRNAs in epithelial-to-mesenchymal transition-induced cancer stem cells: Therapeutic approaches in cancer. Expert Opin. Ther. Targets 2015, 19, 285-297. [CrossRef] [PubMed]
85. Zhang, Y., Zheng, L., Huang, J., Gao, F., Lin, X., He, L., Li, D., Li, Z., Ding, Y., Chen, L. MiR-124 radiosensitizes human colorectal cancer cells by targeting PRRX1. PLoS ONE 2014, 9, e93917. [CrossRef] [PubMed]
86. Ma, J., Fang, B., Zeng, F., Ma, C., Pang, H., Cheng, L., Shi, Y., Wang, H., Yin, B., Xia, J., et al. Down-regulation of miR-223 reverses epithelial-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Oncotarget 2015, 6, 1740-1749. [CrossRef] [PubMed]
87. Bai, W., Ye, X., Zhang, M., Zhu, H., Xi, W., Huang, X., Zhao, J., Gu, B., Zheng, G., Yang, A., et al. MiR-200c suppresses TGF- β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer. Int. J. Cancer 2014, 135, 1356-1368. [CrossRef] [PubMed]
88. Meidhof, S., Brabletz, S., Lehmann, W., Preca, B., Mock, K., Ruh, M., Schüler, J., Berthold, M., Weber, A., Burk, U., et al. ZEB1-associated drug resistance in cancer cells is reversed by the class I HDAC inhibitor mocetinostat. EMBO Mol. Med. 2015, 7, 831-847. [CrossRef] [PubMed]
89. Ye, X., Tam, W.L., Shibue, T., Kaygusuz, Y., Reinhardt, F., Eaton, E.N., Weinberg, R.A. Distinct EMT programs control normal mammary stem cells and tumour-initiating cells. Nature 2015, 525, 256-260. [CrossRef] [PubMed]